Rubí M.-H. Velasco Cárdenas

Rubí M.-H. Velasco Cárdenas

Auto-generated profile, based on publicly available information

Rubí M.-H. Velasco Cárdenas

Faculty of Biology, University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
ASAndrea Schmidts
Andrea Schmidts
MOMaria Ormhøj
Maria Ormhøj
BCBryan D. Choi
Bryan D. Choi
ATAllison O. Taylor
Allison O. Taylor
ABAmanda A. Bouffard
Amanda A. Bouffard
MMMarcela V. Maus
Marcela V. Maus
Chimeric antigen receptor (CAR) T cells (CARTs) have shown tremendous potential for the treatment of certain B-cell malignancies, including patients with relapsed/refractory multiple myeloma (MM). Targeting the B-cell maturation antigen (BCMA) has produced the most promising results for CART therapy of MM to date, but not all remissions are sustained. Emergence of BCMA escape variants has been reported under the selective pressure of monospecific anti-BCMA CART treatment. Thus, there is a clinical need for continuous improvement of CART therapies for MM. Here, we show that a novel trimeric APRIL (a proliferation-inducing ligand)–based CAR efficiently targets both BCMA+ and BCMA− MM. Modeled after the natural ligand-receptor pair, APRIL-based CARs allow for bispecific targeting of the MM-associated antigens BCMA and transmembrane activator and CAML interactor (TACI). However, natural ligands as CAR antigen-binding domains may require further engineering to promote optimal binding and multimerization to adequately trigger T-cell activation. We found that using a trimeric rather than a monomeric APRIL format as the antigen-binding domain enhanced binding to BCMA and TACI and CART activity against MM in vitro and in vivo. Dual-specific, trimeric APRIL-based CAR are a promising therapeutic approach for MM with potential for preventing and treating BCMA escape.

1 May 2019 in Immunity
Verified
Journal Article
Closed access
JWJingxia Wu
Jingxia Wu
SMSicong Ma
Sicong Ma
RSRoger Sandhoff
Roger Sandhoff
YMYanan Ming
Yanan Ming
AHAgnes Hotz-Wagenblatt
Agnes Hotz-Wagenblatt
GCGuoliang Cui
Guoliang Cui

2 February 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
GPGuillermo Valencia Pacheco
Guillermo Valencia Pacheco
INIrene B. Novelo Noh
Irene B. Novelo Noh
RCRubí M.-H. Velasco Cárdenas
Rubí M.-H. Velasco Cárdenas
ARAngélica V. Angulo Ramírez
Angélica V. Angulo Ramírez
RVRicardo F. López Villanueva
Ricardo F. López Villanueva
NCNubia A. Rivero Cárdenas
Nubia A. Rivero Cárdenas
Background: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease involving multiple organs. It is currently accepted that several genetic, environmental, and hormonal factors contributing to its development. Innate immunity may have a great influence in autoimmunity through Toll-like receptors (TLR). TLR-7 recognizing single-strand RNA has been involved in SLE. Its activation induces intracellular signal with attraction of MyD88 and NF-kB, leading to IFN-α synthesis which correlate with disease activity. Objective: To assess the expression of TLR-7, MyD88 and NF-kB in mononuclear cells of Mayan women with SLE. Methods: One hundred patients with SLE and one hundred healthy controls, all them Mayan women, were included. TLR-7 was analyzed on B and T lymphocytes, and MyD88 and NF-kB only in B lymphocytes. Serum INF-α level was evaluated by ELISA. Results: Significant expression (p < 0.0001) of TLR-7 in B and T lymphocytes and serum IFN-α increased (p = 0.034) was observed in patients. MyD88 and NF-kB were also increased in B lymphocytes of patients. TLR-7 and NF-kB expression correlated, but no correlation with INF-α and disease activity was detected. Conclusion: Data support the role of TLR-7 and signal proteins in the pathogenesis of SLE in the Mayan population of Yucatán.

12 September 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
AMAna Valeria Meléndez
Ana Valeria Meléndez
RCRubí M.-H. Velasco Cárdenas
Rubí M.-H. Velasco Cárdenas
SLSimon Lagies
Simon Lagies
JSJuliane Strietz
Juliane Strietz
LSLina Siukstaite
Lina Siukstaite
SMSusana Minguet
Susana Minguet
The link between cancer and aberrant glycosylation has recently become evident. Glycans and their altered forms, known as tumour-associated carbohydrate antigens (TACAs), are diverse, complex and difficult to target therapeutically. Lectins are naturally occurring glycan-binding proteins that offer a unique opportunity to recognise TACAs. T cells expressing chimeric antigen receptors (CARs) have proven to be a successful immunotherapy against leukaemias, but so far have shown limited success in solid tumours. We developed a panel of lectin-CARs that recognise the glycosphingolipid globotriaosylceramide (Gb3), which is overexpressed in various cancers, such as Burkitt's lymphoma, colorectal, breast and pancreatic. We have selected the following lectins: Shiga toxin's B-subunit from Shigella dysenteriae, LecA from Pseudomonas aeruginosa, and the engineered lectin Mitsuba from Mytilus galloprovincialis as antigen-binding domains and fused them to a well-known second-generation CAR. The Gb3-binding lectin-CARs have demonstrated target-specific cytotoxicity against Burkitt's lymphoma-derived cell lines as well as solid tumour cells from colorectal and triple-negative breast cancer. Our findings reveal the big potential of lectin-based CARs as therapeutical applications to target Gb3 and other TACAs expressed in haematological malignancies and solid tumours.

19 November 2020 in Nature Immunology
Verified
Journal Article
Open access
PDF file
FHFrederike A. Hartl
Frederike A. Hartl
EBEsmeralda Beck-Garcìa
Esmeralda Beck-Garcìa
NWNadine M Woessner
Nadine M Woessner
LFLea J. Flachsmann
Lea J. Flachsmann
RCRubí M.-H. Velasco Cárdenas
Rubí M.-H. Velasco Cárdenas
SMSusana Minguet
Susana Minguet
An amendment to this paper has been published and can be accessed via a link at the top of the paper.